NO830935L - Fremgangsmaate for fremstilling av nye konjugater som ved kovalent binding binder sammen et enzym og et antistoff - Google Patents

Fremgangsmaate for fremstilling av nye konjugater som ved kovalent binding binder sammen et enzym og et antistoff

Info

Publication number
NO830935L
NO830935L NO830935A NO830935A NO830935L NO 830935 L NO830935 L NO 830935L NO 830935 A NO830935 A NO 830935A NO 830935 A NO830935 A NO 830935A NO 830935 L NO830935 L NO 830935L
Authority
NO
Norway
Prior art keywords
antibody
preparation
conjugates
bindes
enzym
Prior art date
Application number
NO830935A
Other languages
English (en)
Other versions
NO166618C (no
NO166618B (no
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9272107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO830935(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO830935L publication Critical patent/NO830935L/no
Publication of NO166618B publication Critical patent/NO166618B/no
Publication of NO166618C publication Critical patent/NO166618C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO830935A 1982-03-17 1983-03-16 Fremgangsmaate for fremstilling av immunoenzymatiske konjugater som ved kovalent binding binder sammen et enzym og et antistoff. NO166618C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8204547A FR2523445A1 (fr) 1982-03-17 1982-03-17 Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues

Publications (3)

Publication Number Publication Date
NO830935L true NO830935L (no) 1983-09-19
NO166618B NO166618B (no) 1991-05-13
NO166618C NO166618C (no) 1991-08-21

Family

ID=9272107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO830935A NO166618C (no) 1982-03-17 1983-03-16 Fremgangsmaate for fremstilling av immunoenzymatiske konjugater som ved kovalent binding binder sammen et enzym og et antistoff.

Country Status (27)

Country Link
US (1) US4762707A (no)
EP (1) EP0089880B1 (no)
JP (1) JPH0653677B2 (no)
KR (1) KR910000029B1 (no)
AT (1) ATE27915T1 (no)
AU (1) AU563356B2 (no)
CA (1) CA1216791A (no)
CS (1) CS268656B2 (no)
DD (1) DD209578A5 (no)
DE (1) DE3372175D1 (no)
DK (1) DK166966B1 (no)
EG (1) EG15882A (no)
ES (1) ES8405071A1 (no)
FI (1) FI830897L (no)
FR (1) FR2523445A1 (no)
GR (1) GR77119B (no)
HU (1) HU189246B (no)
IE (1) IE54624B1 (no)
IL (1) IL68106A0 (no)
MA (1) MA19742A1 (no)
NO (1) NO166618C (no)
NZ (1) NZ203586A (no)
OA (1) OA07388A (no)
PH (1) PH18890A (no)
PL (1) PL142316B1 (no)
PT (1) PT76394B (no)
ZA (1) ZA831833B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
DE3612643A1 (de) * 1985-12-05 1987-06-11 Mueller Lierheim Kg Biolog Lab Traegerkoerper, der durch kovalent an seine oberflaeche gebundene antikoerper bioaktiviert ist
WO1987004164A1 (en) * 1986-01-06 1987-07-16 The University Of Melbourne Technetium-antibody conjugate
US5716990A (en) * 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
FR2624010B1 (fr) * 1987-12-07 1991-07-05 Fabre Pierre Cosmetique Compositions topiques heterogenes a base de microgranules de cafeine et/ou de ses derives, utiles comme amincissant et/ou dans le traitement de la cellulite, ainsi que leur preparation
DE3807904A1 (de) * 1988-03-10 1989-09-21 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0449998A4 (en) * 1989-06-30 1992-01-15 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
KR100236375B1 (ko) * 1989-12-11 1999-12-15 오트리브 데이비스 더블유 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트
AU595786B3 (en) * 1990-01-10 1990-03-12 Chung Ming Pan Spray head assembly
US6312939B1 (en) 1992-12-04 2001-11-06 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
US5965106A (en) * 1992-03-04 1999-10-12 Perimmune Holdings, Inc. In vivo binding pair pretargeting
EP0590109A4 (en) * 1992-03-04 1995-04-19 Akzo Nv PRE-TARGETING PAIR LINK -i (IN VIVO).
WO1993023080A1 (en) * 1992-05-13 1993-11-25 The Beth Israel Hospital Association Targeted activated species cytotoxicity
DK75593D0 (no) * 1993-06-25 1993-06-25 Novo Nordisk As
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
CA2606259A1 (en) * 2005-04-27 2006-11-02 Avici Systems An application specific reconfigurable network processor
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
CN107206103A (zh) * 2015-01-23 2017-09-26 赫利克斯生物药品公司 用于治疗目的的抗体‑脲酶缀合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS53124682A (en) * 1977-04-08 1978-10-31 Asahi Chem Ind Co Ltd Preparation of complex of enzyme and bioactive substance and its use
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5590858A (en) * 1978-12-29 1980-07-09 Asahi Chem Ind Co Ltd Method of measuring substance
JPS588395B2 (ja) * 1979-08-08 1983-02-15 大日本製薬株式会社 マレイミド安息香酸誘導体の製法
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique

Also Published As

Publication number Publication date
GR77119B (no) 1984-09-07
DE3372175D1 (en) 1987-07-30
FI830897L (fi) 1983-09-18
OA07388A (fr) 1984-11-30
PH18890A (en) 1985-10-25
DK121683D0 (da) 1983-03-16
CA1216791A (en) 1987-01-20
PL142316B1 (en) 1987-10-31
CS173783A2 (en) 1989-08-14
NO166618C (no) 1991-08-21
EG15882A (en) 1986-09-30
IE54624B1 (en) 1989-12-20
MA19742A1 (fr) 1983-10-01
AU1250483A (en) 1983-09-22
EP0089880B1 (fr) 1987-06-24
ZA831833B (en) 1983-11-30
AU563356B2 (en) 1987-07-09
EP0089880A1 (fr) 1983-09-28
FR2523445A1 (fr) 1983-09-23
DK121683A (da) 1983-09-18
IL68106A0 (en) 1983-06-15
NO166618B (no) 1991-05-13
DK166966B1 (da) 1993-08-09
ES520692A0 (es) 1984-05-16
PL241047A1 (en) 1983-10-10
PT76394B (fr) 1985-12-05
JPS58208238A (ja) 1983-12-03
NZ203586A (en) 1986-08-08
US4762707A (en) 1988-08-09
KR910000029B1 (ko) 1991-01-19
ES8405071A1 (es) 1984-05-16
CS268656B2 (en) 1990-04-11
JPH0653677B2 (ja) 1994-07-20
DD209578A5 (de) 1984-05-16
FR2523445B1 (no) 1985-01-11
ATE27915T1 (de) 1987-07-15
PT76394A (fr) 1983-04-01
IE830531L (en) 1983-09-17
HU189246B (en) 1986-06-30
FI830897A0 (fi) 1983-03-17
KR840003815A (ko) 1984-10-04

Similar Documents

Publication Publication Date Title
NO830935L (no) Fremgangsmaate for fremstilling av nye konjugater som ved kovalent binding binder sammen et enzym og et antistoff
DE69434286D1 (de) Immunologische bestimmungen von prostata-spezifischem antigen
ES8101384A1 (es) Procedimiento de preparacion de productos citotoxicos
DK1226177T3 (da) Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
NO20061203L (no) Fremgangsmate og sammensetning for rekontormering av multiepitopiske antigener for a initiere en immunrespons
ATE128986T1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
ZA875176B (en) Immunotozins,process for their preparation and pharmaceutical compositions in which they are present
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
NO882518D0 (no) Fremgangsmaater ved forbedret binding til antistoff, antistoff-fragmenter, hormoner og andre bindingsmidler, og konjugater derav.
WO2023192289A3 (en) Anti-trophoblast cell surface antigen 2 (trop-2) antibodies
PT76274A (en) Antibodies and antigens useful in the diagnosis and treatment of cancer